Speak English as primary language
Normal or corrected to normal vision
Normal hearing
With or without a diagnosis of an autism spectrum disorder or Asperger syndrome
Cannot speak sentence length English
Vision problems (uncorrected)
Hearing problems

Radiologists with different levels of experience
Healthy adults, with college or advanced degree
Normal or corrected to normal vision
Non-English speaking
Pregnant or lactating
Presence of pacemaker, aneurysm clips, or any metal in the body
A history of welding or grinding
Claustraphobia

Able to understand and provide consent
1. Unstable or significant medical conditions that affect oxidative stress

Histological diagnosis of clear cell renal cell carcinoma (pure or mixed) with radiologic or histologic evidence of metastatic disease
Prior cancer treatment must be completed at least 14 dats prior to study registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade 1 or less baseline
ECOG Performance Status 0-1 within 28 days prior to registration
Demonstrate adequate organ function based on necessary screening labs to be obtained within 28 days prior to registration
Females of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration
Active infection requiring systemic therapy
Brain metastases or spinal cord compression
Pregnant or breastfeeding
Treatment with any investigational drug within 14 days prior to study registration
Current or prior use of immunosuppresive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses

Cognitively-normal H&Y stage 1 PD patients. A physician-documented parkinsonian symptom onset between the ages of 40-59. 1st visit prior to age 65. PD stage I diagnosis must be documented for a min of 2 years.
Cognitively-normal H&Y stage 2 PD patients. H&Y stage 2, as defined by an exam in the practically defined “off” state, and have a diagnosis of PD at the age of 59 or younger. 1st visit prior to age 65
Healthy participants between ages 40-64 at their first visit.
Able and willing to provide informed consent
Fluent in written and spoken English
Parkinson-plus syndrome
Dementia
Previous antipsychotic or anti-dopamine drug therapy
Traumatic head injury
Other neurological diseases or disorders

Polycystic ovary syndrome (PCOS)
BMI >=25 to <=45
In good general health
Willing to avoid pregnancy for duration of study
Currently pregnant or desire of pregnancy
Currently breastfeeding
Untreated thyroid disease
Untreated hyperprolactinemia
Type 1 or Type 2 diabetes

Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Prior treatment of Humira or other biologics for the treatment of HS

Relapsed or refractory B-cell or T-cell ALL after multi-agent chemotherapy(≥ 5% marrow lymphoblasts, assessed by morphology and flow cytometry
ECOG performance status 0-2
Creatinine clearance of at least 50 mL/min within 7 days prior to first dose of study agent
Adequate liver function with AST/ALT less than 3X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent
Circulating WBC count must not be above 20 x10^9/L within 7 days prior to first dose of study agent
Pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol
Evidence of isolated extramedullary relapse (i.e., testicular or CNS)
Serious medical or psychiatric illness that in the opinion of the primary investigator is likely to interfere with study participation may not be enrolled
Poorly controlled HIV, or CD4 < 400. HIV positive patients are allowed on this study if they have a CD4 count greater than or equal to 400, and are on a stable antiviral regimen
Patients with NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia may not be enrolled

Must be 40-80 years of age
Have a diagnosis of IPF within the past 5 years
Unchanged dose of pirfenidone or nintedanib for at least 12 weeks if currently taking these medications
Respiratory exacerbation or hospitalization in the last 3 months
Taking both pirfenidone and nintedanib simultaneously in the past 12 weeks
Lung transplant anticipated during the study
Known history of liver cirrhosis
Active smoker or cessation in the past 12 weeks

Diagnosis of Crohn's disease for 3 months
Ages 18-80
History of other forms of colitis
History of colon polyps (if removed may be eligible) or cancer
Past medical history of toxic megacolon
Current symptomatic diverticulitis or diverticulosis
Past medical history of multiple small bowel resections

A clinical diagnosis of acute ischemic stroke in the MCA territory within 10 hours of symptom onset
Aged 18 to 85 years old, inclusive, at the time of informed consent
Screening NIHSS ≥10
In the judgment of the Investigator, the subject is likely to have supportive care withdrawn in the first day
Commitment to decompressive craniectomy (DC) prior to enrollment
Evidence (clinical or imaging) of concurrent infarction in the contralateral hemisphere deemed by the Investigator to be sufficiently serious so as to affect functional outcome
Clinical signs of herniation and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator’s judgment
Brain hemorrhage (other than small petechial/punctate hemorrhages) on NCCT/MRI

Normal or corrected-to-normal vision
English-speaking
Under age 18

18 years or older
They must consent to participate in research

Native English Speakers
Cannot be non-native English speakers

Be at least 18 years old
Experiencing significant social anxiety
Able to read, write, and understand English
Not struggling with ongoing ongoing alcohol or substance use
Not actively suicidal
Not interested in engaging in mental health treatment
Not socially anxious

18 years of age or greater
Diagnosis of heart failure
English speaking
Unable to provide informed consent

18-65 (inclusive)
Clinical diagnosis of C1-INH Hereditary Angioedema
Clinical diagnosis of FXII/PLG Hereditary Angioedema
Willing to cease use of medication for routine prophylaxis against HAE attacks
History of significant arterial or venous blood clotting
History of uncontrolled abnormal bleeding
Pre-planned surgeries
Known, incurable malignancies

Age ≥ 18 years
Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate).
Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer.
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/MRI of abdomen/pelvis, bone scintigraphy or NaF PET/CT).
Ability to swallow abiraterone acetate tablets as a whole.
Any prior chemotherapy or AR-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone
Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate.
Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy.
Any medical condition for which prednisone (corticosteroid) is contraindicated.
Active infection requiring treatment with antibiotics.

Currently enrolled as a college student
18 years of age or older
Capable of providing informed consent
Diagnosis of a disability
Able to understand written English
Adults unable to provide legal consent
Individuals who are not yet legal adults
Pregnant women
Prisoners

Young adult and adult individuals with Insulin Pump treated Type 1 Diabetes; ages 18-45 years living in and around Central Pennsylvania.
Well established (>6 months) in using an insulin pump to manage diabetes.
A user of Continuous Glucose Monitor (CGM) to measure interstitial glucose levels, and willingness to continue during the study.
Willingness to avoid moderate or strenuous exercise during the study, other than exercise that is part of the study.
Self reported most recent Hgb A1C < 10%.
Contra-indications to engaging in exercise (i.e., health care provider has indicated no/limited activity due to a health condition – as disclosed by the subject)
Uncontrolled hypertension i.e. BP >140/90 mm Hg (ADA criterion) at the assessment visit, measured by the CRC protocol; repeat screening after potential medication adjustment by subjects health care provider is permissible.
Diagnosed significant coronary artery disease, unless written clearance by the subject’s health care provider is given.
Hypoglycemia unawareness
Currently pregnant, breastfeeding or trying to become pregnant during the likely study time frame

18 years of age and older
English speaking individuals
under 18 years old
non english-speaking individuals

Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis within 18 months prior to randomization
Patient has breast cancer that is positive for ER and/or PgR
Patient has HER2-negative breast cancer defined as a negative
Patient has available archival tumor tissue from the surgical specimen, for submission to a central laboratory.
If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines
Patient has received any CDK4/6 inhibitor
Patient has received prior treatment with tamoxifen, raloxifene or AIs
Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for epirubicin.
h a known hypersensitivity to any of the excipients of ribociclib and/or ET (
Patient with distant metastases of breast cancer beyond regional lymph nodes

Diagnosis of PBC
18-75 years of age
On a stable dose of UDCA for 12 months or intolerant to UDCA
Presence of significant hepatic decompensation (liver failure)
History of liver transplantation or currently on transplant list
Other chronic liver disease
Known history of HIV or Hepatitis
History of alcohol or drug abuse

Diagnosis of CLL according to the NCI/IWCLL criteria or SLL according to the WHO criteria
Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy
Age ≥ 18 years and < 70.
ECOG performance status between 0-2.
Life expectancy of ≥ 12 months.
No deletion of 17p13 on cytogenetic analysis by FISH
No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment.
No current use of corticosteroids.
No previous autoimmune complications
No other active primary malignancy

User of the Story feature on Snapchat or Instagram
At least 18 years old
Anyone under the age of 18 years old
Non users of social media

Histologic documentation of women or men with HER2 negative breast carcinoma and free of recurrence.
Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed.
Age > 18 and < 70 years of age.
ECOG performance status 0-2.
Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can be enrolled as long as the ulcers did not cause bleeding requiring a blood transfusion/major intervention.
No history of GI bleeding requiring a blood transfusion, endoscopic or operative intervention.
No history of any prior stroke (hemorrhagic or ischemic).
No concurrent anticoagulation with warfarin, heparin/heparin analogues, clopidogrel, direct thrombin inhibitors, or direct factor XA inhibitors.
No history of atrial fibrillation or myocardial infarction.
No history of grade 4 hypertension, defined as hypertension resulting in lifethreatening consequences

Between ages 18-25
Enrolled at a university
Report 2 days of binge drinking in the past month, defined as 5 or more drinks for men and 4 or more drinks for women in a row
Report at least 1 day of using either tobacco or cannabis in the past year
Can participate in unassisted physical activity
Report having received treatment for substance dependence
Report having a prior diagnosis of substance dependence

Parents must live together
Parents must be expecting their first baby together
We must start working with the couple before the baby is born
Parents must be 18 years or older
Families who can speak and understand English
Single-parent families
Families with more than one-child
Familes who cannot speak or understand English
Families in which one parent is under the age of 18

forestry or climate science related majors (include but not limited to agricultural sciences, environmental resources management, forest ecosystem management, plant science, ecology, biology, meteorology and atmospheric science)
undergraduate or graduate students at Penn State University who are older than 18.
participants should be healthy (without contagious disease)
people under 18
people who are cognitively impaired
people who have contagious disease

Individuals who had some experience with chronic pain over the last 6 months
Living in homes with internet access
Willing to use a smart-home device (Amazon Alexa)
Have access to a smart phone
Read, write, and speak English
Under 18 years old
Major mental health issue that is not currently under advisement of a doctor/therapist
Actively struggling with addiction to substances or newly in recovery
Participants who currently report using mindfulness practices more than 1x a month

18-75 years of age
Diagnosed with Non-Alcoholic Steatohepatitis (NASH) or fatty liver
No new treatment for NASH in the past 6 months
Hepatitis B or C
HIV
Prior or planned liver transplant
Other known causes of chronic liver disease such as cirrhosis
Weight reduction through bariatric surgery in the past 5 years or planned